List view / Grid view
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
Scientists have developed a drug-like molecule to target amyloid-beta, a disordered protein implicated in Alzheimer's disease that has been considered undruggable.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
Binding of SARS-CoV-2 spike proteins to the brain’s endothelial cells can cause the blood-brain barrier to become leaky, potentially causing the neurological symptoms associated with COVID-19.
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
New research reveals that age-related declines in cellular function and proliferation occur in multiple stages, accompanied by different inflammatory responses.
![A coiling protein 'shell,' called a nucleocapsid, shown here, surrounds Ebola's genetic material, which consists of single-strand RNA. University of Delaware researchers are simulating the way molecules of this nucleocapsid move and interact, atom by atom, to understand their functions and expose targets for anti-viral treatments [Credit: Juan Perilla Laboratory].](https://www.drugtargetreview.com/wp-content/uploads/Ebola-nucleocapsid-e1603365997854.jpg)
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
